Generic Clopidoporel Tentative Approval for Indian Generics

Editor: Dominik Stephan

A recent decision by the US Food and Drugs administration opens the US $ six billions market for Indian generics: Sun Pharmaceuticals a major Indian pharmaceuticals company is allowed to market its generic Clopidoporel tablets in the US.

Related Companies

(Picture: Sun)
(Picture: Sun)

Mumbai/India – Sun Pharmaceutical just received a tentative approval by the US Food and Drug Administration (USFDA) for its generic Plavix tablets. This decision clears the way for Sun's new generic drug on the American market.

Suns generic Clopidoporel tablets of 75 mg each are therapeutic equivalent to Sanofi Aventis' Plavix, a common Clopidogrel treatment. Clopidogrels are used to treat acute coronary syndrome, recent myocardial infarction, recent stroke, or established peripheral arterial disease. Market researches estimate that the annual sales volume of Clopidogrel tablets in the US is about US $ six billion.